A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback